Treatment progress of young patients with high-risk diffuse large B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2015.09.016
- VernacularTitle:年轻高危弥漫大B细胞淋巴瘤患者治疗研究进展
- Author:
Yi CHEN
- Publication Type:Journal Article
- Keywords:
Diffuse large B-cell lymphoma;
Young patients;
High-risk;
Prognosis;
Treatment
- From:
Journal of Leukemia & Lymphoma
2015;24(9):566-569
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoid malignancy accounting for 30 ％-40 ％ of all non-Hodgkin lymphoma (NHL).Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present.Conventional chemotherapy, combination of rituximab (R) to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis.This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL.
